Zepbound (tirzepatide) prior authorization denied appeal
GIP/GLP-1 for weight management
Typical PA criteria
- BMI 30 or higher, or BMI 27 with comorbidity
- Lifestyle intervention documented
- Trial and failure of preferred GLP-1 in some plans
Why your PA was denied
- Plan excludes weight-loss drugs
- Step therapy with Wegovy not completed
- BMI or comorbidity documentation missing
- Non-formulary status
Evidence that overturns the denial
- ✓BMI chart with dates
- ✓ICD-10 comorbidity codes (E11.x, I10, G47.33, K76.0)
- ✓Documentation of prior GLP-1 trial intolerance or failure
- ✓SURMOUNT trial citation in letter of medical necessity
Same plan-exclusion risk as Wegovy. Check the plan document before appealing.
Free analysis identifies the cited policy and missing evidence. Then a finished letter that maps your chart to the criteria.
FAQ
Why was my Zepbound (tirzepatide) prior authorization denied?+
The most common reasons are: Plan excludes weight-loss drugs; Step therapy with Wegovy not completed; BMI or comorbidity documentation missing. Your denial letter names the specific criteria you did not meet.
How do I appeal a Zepbound (tirzepatide) denial?+
File a written appeal within 180 days that cites the insurer's clinical policy, includes a letter of medical necessity from the prescriber, and documents the criteria the insurer requires.
What evidence overturns a Zepbound (tirzepatide) denial?+
BMI chart with dates; ICD-10 comorbidity codes (E11.x, I10, G47.33, K76.0); Documentation of prior GLP-1 trial intolerance or failure.
What if the plan excludes Zepbound (tirzepatide) entirely?+
Plan exclusions are different from medical-necessity denials. Check the Summary Plan Description. If the drug is fully excluded, an appeal will not overturn it; you may need a formulary exception or manufacturer assistance program.
Other drugs
- Wegovy (semaglutide)
- Ozempic (semaglutide)
- Mounjaro (tirzepatide)
- Saxenda (liraglutide)
- Humira (adalimumab)